Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase III

Treatment

Active

18 to 65

Other

SHEBA-07-4918-IH-CTIL
NCT00551928

Trial Description

Summary

A phase 3 randomized study that compares high dose Melphalan with the combination of Lenalidomide, Melphalan and steroids as consolidation therapy for newly diagnosed young multiple Myeloma patients that were treated with Lenalidomide and Dexamethasone for first line therapy.

Eligibility Criteria

Inclusion Criteria:

New diagnosis of clinically significant MM

Age up to 65 years

Exclusion Criteria:

Previous therapy

Age over 65 years

Renal failure

Trial Contact Information

Trial Lead Organizations/Sponsors

Chaim Sheba Medical Center

Fo.Ne.Sa.Group of Oncology, Italy

Izhar Hardan, MD

Principal Investigator

Izhar hardan, MD		Ph: +97235302174 Ext.2174
		Email: izhar.hardan@sheba.health.gov.il

Trial Sites

Israel

Tel Hashomer

Hematology department, Sheba Medical center

Izhar Hardan, MD Ph: +972 3 5302174 Ext.2174

Email: izhar.hardan@sheba.health.gov.il

Arnon nagler, MD Ph: +9725305850 Ext.5850

Email: arnon.nagler@sheba.health.gov.il

Izhar Hardan, MD Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00551928
Information obtained from ClinicalTrials.gov on July 16, 2008

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.